AiCT-AsiaPCR 2021

Pushing Boundaries in Tricuspid Therapy –

The TricValve Solution

Friday October 8th 2021
Pushing Boundaries in Tricuspid Therapy –
The TricValve Solution

Our session at AiCT-AsiaPCR addressed the problems of tricuspid regurgitation and explained the unique TricValve Transcatheter Bicaval Valves System solution together with case examples and discussion opportunities.

Hear from the experts

Concluding remark

Prof Haude concluded the session with a key take-home message: “TricValve interventions is a new treatment option for patients with severe TR deemed high-risk for surgery and may be a solution for specific challenges such as pacemaker patients, very dilated annulus or poor leaflet coaptation.”

Learning Objectives

  • To learn about a new treatment strategy with the TricValve Bicaval Valves System for patients suffering from severe tricuspid regurgitation
  • To understand how this novel device can be an alternative option to the conventional treatment
  • To obtain insights into a real live case scenario

Case summary

The patient was a 67-year-old male patient suffering from hypertension and has diabetes mellitus and hyperlipidemia posing as cardiovascular risk factors. He had a cardiac history with ischemic cardiomyopathy. In 1999, he underwent an Orthotopic heart transplantation and in 2011, during IVUS controls, a cardiac allograft vasculopathy was detected. His medication treatments were then switched to Prograf + Clopidogrel. The patient had chronic anemia due to colonic angiodysplasia which was treated with laser therapy. In 2017, he underwent extra-anatomic axillobifemoral bypass due to severe peripheral vasculopathy. The bifemoral bypass presented problems in the access of the TricValve® implantation therefore puncture sites were done with echo guidance to facilitate access. Due to the heart transplantation, the mid SVC was very dilated and the valve needed to be implanted as high as possible and taking care not to occlude the innominate vein. Both the SVC and IVC valves were implanted successfully. 10 months clinical follow-up after implantation showed a good clinical outcome without signs of heart failure and  a good coaptation in both SVC and IVC.